Trevi Therapeutics (TRVI) Other Gross PP&E Adjustments (2018 - 2026)
Trevi Therapeutics (TRVI) recorded quarterly Other Gross PP&E Adjustments of -$610000.0 in Q1 2026, down 335.71% quarter-over-quarter from -$140000.0 in Q4 2025, and up 29.48% on a YoY basis from -$471116.1 in Q1 2025.
Trevi Therapeutics (TRVI) Other Gross PP&E Adjustments (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Other Gross PP&E Adjustments history runs 9 years deep, the most recent figure standing at -$610000.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 29.48% year-over-year to -$610000.0; the TTM figure through Mar 2026 stood at -$610000.0 (up 29.48% YoY), while the FY2025 annual figure was -$140000.0, up 73.58% from the prior year.
- Other Gross PP&E Adjustments was -$610000.0 for Q1 2026 at Trevi Therapeutics, down from -$140000.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $371000.0 in Q4 2022 to a low of -$1.3 million in Q1 2023.
- Historically, Other Gross PP&E Adjustments has averaged -$535875.0 across 5 years, with a median of -$570000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Other Gross PP&E Adjustments surged 256.73% in 2022, then slumped 2145.28% in 2023.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $371000.0 in 2022, then tumbled by 61.19% to $144000.0 in 2023, then tumbled by 468.06% to -$530000.0 in 2024, then surged by 73.58% to -$140000.0 in 2025, then slumped by 335.71% to -$610000.0 in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$610000.0 (Q1 2026), -$140000.0 (Q4 2025), and -$741000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -60,691.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -83,048.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -285.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -892,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -1.69 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Trevi Therapeutics | 2.08 Bn | 1.91 Bn | - | -610,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -610,000.00 |
| Mar 31, 2026 | -610,000.00 |
| Dec 31, 2025 | -140,000.00 |
| Dec 31, 2025 | -140,000.00 |
| Sep 30, 2025 | -741,000.00 |
| Sep 30, 2025 | -741,000.00 |
| Mar 31, 2025 | -865,000.00 |
| Mar 31, 2025 | -865,000.00 |
| Dec 31, 2024 | -530,000.00 |
| Dec 31, 2024 | -530,000.00 |
| Sep 30, 2024 | -973,000.00 |
| Sep 30, 2024 | -973,000.00 |
| Jun 30, 2024 | -181,000.00 |
| Jun 30, 2024 | -181,000.00 |
| Mar 31, 2024 | -1.08 Mn |
| Mar 31, 2024 | -1.08 Mn |
| Dec 31, 2023 | 144,000.00 |
| Dec 31, 2023 | 144,000.00 |
| Sep 30, 2023 | -1.19 Mn |
| Sep 30, 2023 | -1.19 Mn |